Intas Pharmaceuticals Limited — Voriconazole Exporter Profile
Indian Pharmaceutical Exporter · #7 for Voriconazole · $1.4M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #7 Indian exporter of Voriconazole with $1.4M in export value and 92 verified shipments. Intas Pharmaceuticals Limited holds a 4.5% market share in Voriconazole exports across 14 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Voriconazole Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Voriconazole?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED KINGDOM | $946.6K | 38 | 74.8% |
| GREECE | $133.7K | 7 | 10.6% |
| POLAND | $65.0K | 5 | 5.1% |
| HONG KONG | $50.0K | 1 | 4.0% |
| COLOMBIA | $20.8K | 1 | 1.6% |
| SPAIN | $16.5K | 3 | 1.3% |
| NETHERLANDS | $8.7K | 2 | 0.7% |
| SINGAPORE | $8.4K | 2 | 0.7% |
| AUSTRIA | $7.1K | 2 | 0.6% |
| SWITZERLAND | $4.6K | 2 | 0.4% |
Intas Pharmaceuticals Limited exports Voriconazole to 14 countries. The largest destination is UNITED KINGDOM accounting for 74.8% of Intas Pharmaceuticals Limited's Voriconazole shipments, followed by GREECE (10.6%) and POLAND (5.1%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Voriconazole from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| FAWDON MANUFACTURING CENTRE ( SF ) | UNITED KINGDOM | $735.2K | 25 |
| ACCORD UK | UNITED KINGDOM | $152.1K | 8 |
| ACCORD HEALTHCARE SINGLE MEMBER SA | GREECE | $133.7K | 7 |
| FAWDON MANUFACTURING CENTRE SF | UNITED KINGDOM | $59.3K | 5 |
| TO THE ORDER | MALTA | $56.1K | 15 |
| TO THE ORDER., | HONG KONG | $50.0K | 1 |
| XINETIX PHARMA SAS AND PHAREX | COLOMBIA | $20.8K | 1 |
| ACCORD HEALTHCARE, SLU | SPAIN | $16.5K | 3 |
| ACCORD HEALTHCARE POLSKA SP. Z O.O. | POLAND | $15.3K | 2 |
| ACCORD HEALTHCARE POLSKA SP. Z.O.O. | POLAND | $11.0K | 1 |
Intas Pharmaceuticals Limited supplies Voriconazole to 20 buyers globally. The largest buyer is FAWDON MANUFACTURING CENTRE ( SF ) (UNITED KINGDOM), followed by ACCORD UK (UNITED KINGDOM) and ACCORD HEALTHCARE SINGLE MEMBER SA (GREECE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Voriconazole Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $19.6M worth of Voriconazole through 1,413 shipments from 144 suppliers to 114 countries, serving 393 buyers globally. Intas Pharmaceuticals Limited contributes $1.4M to this total, accounting for 4.5% of India's Voriconazole exports. Intas Pharmaceuticals Limited ships Voriconazole to 14 countries through 20 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Voriconazole Exports?
Intas Pharmaceuticals Limited's average Voriconazole shipment value is $15.2K per consignment, based on 92 shipments totaling $1.4M. The largest destination is UNITED KINGDOM (74.8% of Intas Pharmaceuticals Limited's Voriconazole exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Voriconazole Exporters?
Intas Pharmaceuticals Limited ranks #7 among 144 Indian Voriconazole exporters with a 4.5% market share. The top 3 exporters are SANDOZ PRIVATE LIMITED ($7.3M), MSN LABORATORIES PRIVATE LIMITED ($2.5M), ASPIRO PHARMA LIMITED ($1.4M). Intas Pharmaceuticals Limited processed 92 shipments to 14 destination countries.
What Voriconazole Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHA.DRU & MEDI, VORICONAZOLE 200MG10TPP(ACCORD-EU(POD) EACH FILM COATED TABLET CONTAINS VORICONAZOLE PH EUR | $246.7K | 6 |
| PHA.DRU & MEDI, VORICONAZOLE 200MG14T CRO(ACO-EU(POD) EACH FILM COATED TABLET CONTAINS: VORICONAZOLE PH.EUR | $225.6K | 6 |
| PHARMACEUTICAL DRUGS AND MEDICINE VORICONAZOL 200MG 14T PP(ACCORD-EU(POD) EACH FILM COATED TABLET CONTAINS VORICONAZOLETBS | $139.4K | 3 |
| PHARMA DRUGS MEDI VORICONAZOLE 200MG 10TPP ACCORD EU POD AS PER INVOICE | $100.3K | 3 |
| PHARM DRUG&MED:VORICONAZOLE 200MG 2X14T(ACCORD-PP-UK)EACH FILM COATED TABLET CONTAINS:VORICONAZOLE PH.EUR.20 | $99.2K | 6 |
| PHARMA DRUGS & MEDI VORICONAZOLE 200MG 1 | $87.0K | 6 |
| PHA.DRU & MEDI, VORICONAZOLE 200MG 10TPPACCORD-EUPOD Each film coated tabletcontains Voriconazole Ph Eur 200 mg 1476 | $50.0K | 1 |
| PHARMA DRUGS AND MEDICINE-ACCORD VORICONAZOLE TABLETS 200MG Each film coated tablet contains QTY.1976X2X14T-AS PER INV | $50.0K | 1 |
| PHARMA DRUG&MED:VORICONAZOLE 200MG 2X14T | $40.1K | 1 |
| PHARMA DRUGS AND MEDI VORICONAZOLE 200MG2X14T ACCORD PP PL RO AS PER INV | $38.7K | 2 |
Intas Pharmaceuticals Limited exports 52 distinct Voriconazole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHA.DRU & MEDI, VORICONAZOLE 200MG10TPP(ACCORD-EU(POD) EACH with 6 shipments worth $246.7K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Voriconazole to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Voriconazole to its top destination countries
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Voriconazole Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | MSN LABORATORIES PRIVATE LIMITED | $2.5M | 100 | 11 | $24.8K |
| 6 | ASPIRO PHARMA LIMITED | $1.4M | 59 | 15 | $23.8K |
| 7 | INTAS PHARMACEUTICALS LIMITED ★ | $1.4M | 92 | 14 | $15.2K |
| 8 | MYLAN LABORATORIES LIMITED | $1.4M | 44 | 6 | $31.3K |
| 4 | AJANTA PHARMA LIMITED | $1.4M | 27 | 1 | $50.0K |
Intas Pharmaceuticals Limited ranks #7 among 144 Indian Voriconazole exporters. Average shipment value of $15.2K compared to the market average of $135.8K. The closest competitors by value are MSN LABORATORIES PRIVATE LIMITED and ASPIRO PHARMA LIMITED.
Which Indian Ports Ship Voriconazole Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 256 | 18.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 194 | 13.7% |
| DELHI AIR CARGO ACC (INDEL4) | 112 | 7.9% |
| DELHI AIR | 103 | 7.3% |
| HYDERABAD AIR | 68 | 4.8% |
| Bombay Air | 55 | 3.9% |
| HYDERABAD ACC (INHYD4) | 49 | 3.5% |
| HYDERABAD ICD (INSNF6) | 39 | 2.8% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Voriconazole Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Voriconazole, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Voriconazole — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Voriconazole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 96 individual customs records matching Intas Pharmaceuticals Limited exporting Voriconazole, covering 52 formulations to 14 countries via 20 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 114+ countries, 393+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Voriconazole Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Voriconazole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Voriconazole Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Voriconazole. For current shipment-level data, contact TransData Nexus.